CMT-3. CollaGenex.

Fingleton B
Curr Opin Investig Drugs. 2003 4 (12): 1460-7

PMID: 14763133

CMT-3 is an orally active matrix metalloprotease inhibitor, and one of a series of inhibitors of multiple proteases and cytokines, under development by CollaGenex. The compound is currently undergoing phase II trials for the potential treatment of cancer, in particular metastatic cancer and HIV-related Kaposi's sarcoma.

MeSH Terms (10)

Animals Clinical Trials as Topic Drugs, Investigational Enzyme Inhibitors Humans Matrix Metalloproteinase Inhibitors Matrix Metalloproteinases Neoplasms Technology, Pharmaceutical Tetracyclines

Connections (2)

This publication is referenced by other Labnodes entities:

Links